Thus, memory CD8(+) T cells might be a promising predictor in cancer patients with immunotherapy.<h4>Conclusions</h4>The host's overall immune status, and not only the tumor itself, should be considered to predict the efficacy of immunotherapy in cancer patients. This evidence concerns the gene CD8A and neoplasm.